• Chris R. Kelsey
  • Lynn D. Wilson
Part of the Medical Radiology book series (MEDRAD)


Hodgkin and non-Hodgkin lymphoma represent a diverse spectrum of distinct diseases that arise from the lymphoid system. Lymphomas are characterized by significant biological diversity, heterogeneous presentations, distinct treatment approaches, and ever-changing classification schemes. Prognostic scoring systems have been developed for the most common subtypes using standard clinical and pathological factors. These scoring systems are commonly utilized in clinical practice to guide treatment and assess prognosis. More refined methods of understanding the underlying biology, such as gene expression profiling, are currently being explored. Response to treatment by radiological imaging, particularly positron emission tomography, is instrumental in clinical practice and also has significant prognostic significance.


Positron Emission Tomography Follicular Lymphoma Hodgkin Lymphoma Mantle Cell Lymphoma Anaplastic Lymphoma Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Hodgkin lymphoma


Non-Hodgkin lymphoma


Nodular lymphocyte predominant Hodgkin lymphoma


German Hodgkin Study Group


Doxorubicine, bleomycin, vinblastine, dacarbazine


Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone


Diffuse large B-cell lymphoma


International prognostic index


Follicular lymphoma


Follicular lymphoma international prognostic index


Positron emission tomography


Anaplastic large cell lymphoma


Mucosa associated lymphoid tissue


Primary central nervous system lymphoma


Mycosis fungoides


Whole brain radiation therapy


Lactate dehydrogenase


  1. Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17):3144–3150PubMedGoogle Scholar
  2. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715. doi: 10.1200/JCO.2006.08.2941 JCO.2006.08.2941 [pii]PubMedGoogle Scholar
  3. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28(31):4730–4739. doi: 10.1200/JCO.2009.27.7665 JCO.2009.27.7665 [pii]PubMedGoogle Scholar
  4. Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van ‘t Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24):2396–2406PubMedGoogle Scholar
  5. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van ‘t Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5):1878–1886. doi: 10.1182/blood-2006-07-034405 blood-2006-07-034405 [pii]PubMedGoogle Scholar
  6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511. doi: 10.1038/35000501 PubMedGoogle Scholar
  7. Aviles A, Delgado S (1998) A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin’s disease with bulky disease. Clin Lab Haematol 20(2):95–99PubMedGoogle Scholar
  8. Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz-Maqueo JC (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30(4):799–803PubMedGoogle Scholar
  9. Aviles A, Fernandezb R, Perez F, Nambo MJ, Neri N, Talavera A, Castaneda C, Gonzalez M, Cleto S (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45(7):1385–1389PubMedGoogle Scholar
  10. Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS (2011) End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol 22(4):910–915. doi: 10.1093/annonc/mdq549 mdq549 [pii]PubMedGoogle Scholar
  11. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28(20):3360–3365. doi: 10.1200/JCO.2009.26.3947 JCO.2009.26.3947 [pii]PubMedGoogle Scholar
  12. Bernard M, Tsang RW, Le LW, Hodgson DC, Sun A, Wells W, Kukreti V, Kuruvilla J, Crump M, Gospodarowicz MK (2013) Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma 54(2):261–267. doi: 10.3109/10428194.2012.711828 PubMedGoogle Scholar
  13. Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J (2004) Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59(2):501–508. doi: 10.1016/j.ijrobp.2003.11.001 S0360301603022855 [pii]PubMedGoogle Scholar
  14. Bhatia S, Ramsay NK, Bantle JP, Mertens A, Robison LL (1996) Thyroid Abnormalities after therapy for Hodgkin’s disease in childhood. Oncologist 1(1 & 2):62–67PubMedGoogle Scholar
  15. Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CT, Fuller LM, Mauch P et al (1995) Incidence of second cancers in patients treated for Hodgkin’s disease. J Natl Cancer Inst 87(10):732–741PubMedGoogle Scholar
  16. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14):2835–2841PubMedGoogle Scholar
  17. Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, Ferme C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F (2007) CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 25(7):787–792. doi: 10.1200/JCO.2006.07.0722 JCO.2006.07.0722 [pii]PubMedGoogle Scholar
  18. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dorken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29(32):4234–4242. doi: 10.1200/JCO.2010.33.9549 JCO.2010.33.9549 [pii]PubMedGoogle Scholar
  19. Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Seow A, Pompe-Kirn V, Martos C, Jonasson JG, Colin D, Boffetta P (2005) Second primary cancers among 109 000 cases of non-Hodgkin’s lymphoma. Br J Cancer 93(1):159–166. doi: 10.1038/sj.bjc.6602654 6602654 [pii]PubMedCentralPubMedGoogle Scholar
  20. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Maloney DG, Gopal AK (2011) Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29(22):3023–3029. doi: 10.1200/JCO.2010.33.7055 JCO.2010.33.7055 [pii]PubMedCentralPubMedGoogle Scholar
  21. Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26(32):5170–5174. doi: 10.1200/JCO.2007.15.1001 JCO.2007.15.1001 [pii]PubMedGoogle Scholar
  22. Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, Connors JM, Savage KJ (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 116(16):3797–3806. doi: 10.1002/cncr.25117 PubMedGoogle Scholar
  23. Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH (2012) Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 118(17):4156–4165. doi: 10.1002/cncr.26687 PubMedGoogle Scholar
  24. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL (2011) 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52(3):386–392. doi: 10.2967/jnumed.110.082586 jnumed.110.082586 [pii]PubMedGoogle Scholar
  25. Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, Jain P, Bishop L, Horwich A, Catovsky D (2003) Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 89(1):36–42. doi: 10.1038/sj.bjc.6601006 6601006 [pii]PubMedCentralPubMedGoogle Scholar
  26. Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM (2010) Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28(1):136–141. doi: 10.1200/JCO.2009.24.0945 JCO.2009.24.0945 [pii]PubMedGoogle Scholar
  27. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494–5502. doi: 10.1158/1078-0432.CCR-09-0113 1078-0432.CCR-09-0113 [pii]PubMedGoogle Scholar
  28. Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS (1984) Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 53(4):878–883PubMedGoogle Scholar
  29. Corry J, Smith JG, Wirth A, Quong G, Liew KH (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41(3):615–620 S0360-3016(97)00571-3 [pii]PubMedGoogle Scholar
  30. De Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27(26):4239–4246. doi: 10.1200/JCO.2008.19.9174 JCO.2008.19.9174 [pii]PubMedGoogle Scholar
  31. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R (1998) Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 92(4):1150–1159PubMedGoogle Scholar
  32. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R (1999) Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol 40(6 Pt 1):914–924 S0190-9622(99)70079-4 [pii]PubMedGoogle Scholar
  33. Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol 17(3):776–783PubMedGoogle Scholar
  34. Dorth JA, Chino JP, Prosnitz LR, Diehl LF, Beaven AW, Coleman RE, Kelsey CR (2011) The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol 22(2):405–410. doi: 10.1093/annonc/mdq389 mdq389 [pii]PubMedGoogle Scholar
  35. Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR (2012) Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 84(3):762–767. doi: 10.1016/j.ijrobp.2011.12.067 S0360-3016(11)03771-0 [pii]PubMedGoogle Scholar
  36. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M (2012) Impact of [18F]Fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol 30(35):4317–4322. doi: 10.1200/JCO.2012.43.0934 JCO.2012.43.0934 [pii]PubMedGoogle Scholar
  37. Eich HT, Muller RP, Engenhart-Cabillic R, Lukas P, Schmidberger H, Staar S, Willich N (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184(8):406–410PubMedGoogle Scholar
  38. Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, Ho A, Dorken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Dohner H, Borchmann P, Muller-Hermelink HK, Muller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27):4199–4206. doi: 10.1200/JCO.2010.29.8018 JCO.2010.29.8018 [pii]PubMedGoogle Scholar
  39. Engert A (2012) Radiotherapy in early-stage Hodgkin lymphoma. The ASCO Post, 15 June 2012Google Scholar
  40. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19):3601–3608PubMedGoogle Scholar
  41. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, Koch P, Hanel M, Pfreundschuh M, Wilhelm M, Trumper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Muller-Hermelink HK, Hasenclever D, Loffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554. doi: 10.1200/JCO.2008.19.8820 JCO.2008.19.8820 [pii]PubMedGoogle Scholar
  42. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652. doi: 10.1056/NEJMoa1000067 PubMedGoogle Scholar
  43. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Kral Z, Fuchs M, Hallek M, Kanz L, Dohner H, Dorken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Muller RP, Dietlein M, Borchmann P, Diehl V (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799. doi: 10.1016/S0140-6736(11)61940-5 S0140-6736(11)61940-5 [pii]PubMedGoogle Scholar
  44. Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA Jr, Fisher RI (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 120(11):903–912PubMedGoogle Scholar
  45. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A (1999) ALK + lymphoma: clinico-pathological findings and outcome. Blood 93(8):2697–2706PubMedGoogle Scholar
  46. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562. doi: 10.1200/JCO.2008.21.3991 JCO.2008.21.3991 [pii]PubMedGoogle Scholar
  47. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van’t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19):1916–1927. doi: 10.1056/NEJMoa064601 357/19/1916 [pii]PubMedGoogle Scholar
  48. Ferreri AJ, Dell’Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E (2000) Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B-cell lymphomas. Oncology 58(3):219–226 ocl58219 [pii]PubMedGoogle Scholar
  49. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266–272PubMedGoogle Scholar
  50. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126. doi: 10.1200/JCO.2005.09.131 JCO.2005.09.131 [pii]PubMedGoogle Scholar
  51. Franklin JG, Paus MD, Pluetschow A, Specht L (2005) Chemotherapy, radiotherapy and combined modality for Hodgkin’s disease, with emphasis on second cancer risk. Cochrane Database Syst Rev (4):CD003187. doi: 10.1002/14651858.CD003187.pub2
  52. Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30(28):3439–3443. doi: 10.1200/JCO.2012.43.5800 JCO.2012.43.5800 [pii]PubMedGoogle Scholar
  53. Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202–1208. doi: 10.1200/JCO.2008.18.1495 JCO.2008.18.1495 [pii]PubMedCentralPubMedGoogle Scholar
  54. Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP (2012) Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30(27):3368–3375. doi: 10.1200/JCO.2011.40.6546 JCO.2011.40.6546 [pii]PubMedCentralPubMedGoogle Scholar
  55. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752. doi: 10.1200/JCO.2007.11.6525 JCO.2007.11.6525 [pii]PubMedGoogle Scholar
  56. Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM, Armitage JO (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 17(6):920–927. doi: 10.1093/annonc/mdl039 mdl039 [pii]PubMedGoogle Scholar
  57. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93(11):3913–3921PubMedGoogle Scholar
  58. Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E (2010) The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115(8):1530–1533. doi: 10.1182/blood-2009-08-236570 blood-2009-08-236570 [pii]PubMedGoogle Scholar
  59. Gervais-Fagnou DD, Girouard C, Laperriere N, Pintillie M, Goss PE (1999) Breast cancer in women following supradiaphragmatic irradiation for Hodgkin’s disease. Oncology 57(3):224–231 12035 [pii] 12035PubMedGoogle Scholar
  60. Girardi M, Heald PW, Wilson LD (2004) The pathogenesis of mycosis fungoides. N Engl J Med 350(19):1978–1988. doi: 10.1056/NEJMra032810 350/19/1978 [pii]PubMedGoogle Scholar
  61. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88(2):202–210. doi: 10.1016/j.radonc.2008.05.012 S0167-8140(08)00241-7 [pii]PubMedGoogle Scholar
  62. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P (1998) Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 46(1):51–62 S0167814097001254 [pii]PubMedGoogle Scholar
  63. Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Tsang RW (2010) Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 116(16):3815–3824. doi: 10.1002/cncr.25226 PubMedGoogle Scholar
  64. Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, Stevenson MA, Mauch P (2006) Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 64(3):928–934. doi: 10.1016/j.ijrobp.2005.08.010 S0360-3016(05)02375-8 [pii]PubMedGoogle Scholar
  65. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24(19):3121–3127. doi: 10.1200/JCO.2005.05.1003 JCO.2005.05.1003 [pii]PubMedGoogle Scholar
  66. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106(4):1376–1381. doi: 10.1182/blood-2005-01-0272 2005-01-0272 [pii]PubMedGoogle Scholar
  67. Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK (2012) Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys 83(5):e647–e654. doi: 10.1016/j.ijrobp.2012.01.060 S0360-3016(12)00133-2 [pii]PubMedGoogle Scholar
  68. Hancock SL, Cox RS, McDougall IR (1991) Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 325(9):599–605. doi: 10.1056/NEJM199108293250902 PubMedGoogle Scholar
  69. Hancock SL, Tucker MA, Hoppe RT (1993a) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85(1):25–31PubMedGoogle Scholar
  70. Hancock SL, Tucker MA, Hoppe RT (1993b) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270(16):1949–1955PubMedGoogle Scholar
  71. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. doi: 10.1182/blood-2003-05-1545 2003-05-1545 [pii]PubMedGoogle Scholar
  72. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dolken G, Naumann R, Knauf W, Freund M, Rohrberg R, Hoffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grunhagen U (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25(15):1986–1992. doi: 10.1200/JCO.2006.06.4618 JCO.2006.06.4618 [pii]PubMedGoogle Scholar
  73. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725–3732PubMedGoogle Scholar
  74. Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, Glick JH (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22(15):3032–3038. doi: 10.1200/JCO.2004.06.088 JCO.2004.06.088 [pii]PubMedGoogle Scholar
  75. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565. doi: 10.1182/blood-2007-06-095331 blood-2007-06-095331 [pii]PubMedGoogle Scholar
  76. Hull MC, Morris CG, Pepine CJ, Mendenhall NP (2003) Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 290(21):2831–2837PubMedGoogle Scholar
  77. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52–59PubMedGoogle Scholar
  78. Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD (2005) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23(21):4652–4661. doi: 10.1200/JCO.2005.01.891 JCO.2005.01.891 [pii]PubMedGoogle Scholar
  79. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578. doi: 10.1200/JCO.2006.08.2305 JCO.2006.08.2305 [pii]PubMedGoogle Scholar
  80. Kim YH, Bishop K, Varghese A, Hoppe RT (1995) Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 131(9):1003–1008PubMedGoogle Scholar
  81. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139(7):857–866. doi: 10.1001/archderm.139.7.857 139/7/857 [pii]PubMedGoogle Scholar
  82. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, Loeffler M, Trumper L, Pfreundschuh M, Siebert R (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leukemia 22(12):2226–2229. doi: 10.1038/leu.2008.230 leu2008230 [pii]PubMedGoogle Scholar
  83. Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, Prosnitz LR (2006) Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin’s disease: cure balanced against complications. J Clin Oncol 24(4):605–611PubMedGoogle Scholar
  84. Kupeli S, Hazirolan T, Varan A, Akata D, Alehan D, Hayran M, Besim A, Buyukpamukcu M (2010) Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol 28(6):1025–1030. doi: 10.1200/JCO.2009.25.2627 JCO.2009.25.2627 [pii]PubMedGoogle Scholar
  85. Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22(1):62–68PubMedGoogle Scholar
  86. Lavey RS, Eby NL, Prosnitz LR (1990) Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 66(1):80–88PubMedGoogle Scholar
  87. Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM (2003) Limited-stage mantle-cell lymphoma. Ann Oncol 14(10):1555–1561PubMedGoogle Scholar
  88. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323. doi: 10.1056/NEJMoa0802885 359/22/2313 [pii]PubMedGoogle Scholar
  89. Levy M, Copie-Bergman C, Gameiro C, Chaumette MT, Delfau-Larue MH, Haioun C, Charachon A, Hemery F, Gaulard P, Leroy K, Delchier JC (2005) Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 23(22):5061–5066PubMedGoogle Scholar
  90. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30 + cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49(6):1049–1058. doi: 10.1016/S0190 S0190962203024848 [pii]PubMedGoogle Scholar
  91. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 100(1):86–92. doi: 10.1016/j.radonc.2011.05.013 S0167-8140(11)00205-2 [pii]PubMedGoogle Scholar
  92. Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14(4):1282–1290PubMedGoogle Scholar
  93. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579–4586. doi: 10.1200/JCO.2007.13.5376 JCO.2007.13.5376 [pii]PubMedGoogle Scholar
  94. Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, Pruneri G, Preda L, Piperno G, Gospodarowicz M, Cavalli F, Moreno Gomez H (2009) Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (IELSG 4) [corrected]. Leuk Lymphoma 50(6):925–931. doi: 10.1080/10428190902912478 911751509 [pii]PubMedGoogle Scholar
  95. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200–207. doi: 10.1200/JCO.2010.30.0368 JCO.2010.30.0368 [pii]PubMedCentralPubMedGoogle Scholar
  96. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366(5):399–408. doi: 10.1056/NEJMoa1111961 PubMedCentralPubMedGoogle Scholar
  97. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT. Leuk Lymphoma 39(5–6):543–553 I308J001131 [pii]PubMedGoogle Scholar
  98. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339(1):21–26PubMedGoogle Scholar
  99. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC (2006) Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107(7):2912–2919. doi: 10.1182/blood-2005-08-3392 2005-08-3392 [pii]PubMedGoogle Scholar
  100. Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC (2006) Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J Clin Oncol 24(10):1568–1574. doi: 10.1200/JCO.2005.04.2200 JCO.2005.04.2200 [pii]PubMedGoogle Scholar
  101. Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B-cell lymphoma. J Pathol 208(5):714–723. doi: 10.1002/path.1924 PubMedGoogle Scholar
  102. Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, Sun A, Hodgson DC (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49(8):1486–1493. doi: 10.1080/10428190802140873 793642260 [pii]PubMedGoogle Scholar
  103. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 20(18):3765–3771PubMedGoogle Scholar
  104. Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M (2001) Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 48(4):454–460PubMedCentralPubMedGoogle Scholar
  105. Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS (2008) LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 26(3):447–454. doi: 10.1200/JCO.2007.13.0690 JCO.2007.13.0690 [pii]PubMedGoogle Scholar
  106. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20(8):2101–2108PubMedGoogle Scholar
  107. Niitsu N, Okamoto M, Miura I, Hirano M (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23(4):777–783. doi: 10.1038/leu.2008.344 leu2008344 [pii]PubMedGoogle Scholar
  108. Nogova L, Reineke T, Eich HT, Josting A, Muller-Hermelink HK, Wingbermuhle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Muller RP, Diehl V, Engert A (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16(10):1683–1687. doi: 10.1093/annonc/mdi323 mdi323 [pii]PubMedGoogle Scholar
  109. Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, Bredenfeld H, Skripnitchenko R, Muller RP, Muller-Hermelink HK, Diehl V, Engert A (2008) Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26(3):434–439. doi: 10.1200/JCO.2007.11.8869 JCO.2007.11.8869 [pii]PubMedGoogle Scholar
  110. Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2012) Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. doi: 10.1093/annonc/mds429 mds429 [pii]PubMedGoogle Scholar
  111. Noordijk EM, Thomas J, Ferme C, van ‘t Veer MB, Brice P, Divine M, Morschhauser F, Carde P, Eghbali H, Henry-Amar M (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Proc ASCO 23(June 1 Supplement):6505Google Scholar
  112. Noy A, Yahalom J, Zaretsky L, Brett I, Zelenetz AD (2005) Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. J Clin Oncol 23(16):3768–3772. doi: 10.1200/JCO.2005.10.018 23/16/3768 [pii]PubMedGoogle Scholar
  113. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppa S (2009) Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 22(8):1094–1101. doi: 10.1038/modpathol.2009.73 modpathol200973 [pii]PubMedGoogle Scholar
  114. Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62(10):1595–1600. doi: 10.1001/archneur.62.10.1595 62/10/1595 [pii]PubMedGoogle Scholar
  115. Ono S, Kato M, Takagi K, Kodaira J, Kubota K, Matsuno Y, Komatsu Y, Asaka M (2010) Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol 25(4):804–809. doi: 10.1111/j.1440-1746.2009.06204.x JGH6204 [pii]PubMedGoogle Scholar
  116. Pavlovsky S, Maschio M, Santarelli MT, Muriel FS, Corrado C, Garcia I, Schwartz L, Montero C, Sanahuja FL, Magnasco O et al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 80(18):1466–1473PubMedGoogle Scholar
  117. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21(24):4489–4495. doi: 10.1200/JCO.2003.04.056 JCO.2003.04.056 [pii]PubMedGoogle Scholar
  118. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391PubMedGoogle Scholar
  119. Phan J, Mazloom A, Jeffrey Medeiros L, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170–4176. doi: 10.1200/JCO.2009.27.3441 JCO.2009.27.3441 [pii]PubMedGoogle Scholar
  120. Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48(9):1721–1727. doi: 10.1080/10428190701559140 781796832 [pii]PubMedGoogle Scholar
  121. Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U (2012) Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119(9):2066–2073. doi: 10.1182/blood-2011-06-359943 blood-2011-06-359943 [pii]PubMedGoogle Scholar
  122. Pugh TJ, Ballonoff A, Newman F, Rabinovitch R (2010) Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer 116(16):3843–3851. doi: 10.1002/cncr.25149 PubMedGoogle Scholar
  123. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD (2010) Prognostic factors in follicular lymphoma. J Clin Oncol 28(17):2902–2913. doi: 10.1200/JCO.2009.26.1693 JCO.2009.26.1693 [pii]PubMedGoogle Scholar
  124. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947PubMedGoogle Scholar
  125. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, Megraud F, Palazzo L, de Mascarel A, Molina T, Rambaud JL (2001) Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48(3):297–303PubMedGoogle Scholar
  126. Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, Schulz H, Kraemer W, Boersch G, Rohde P, Seifert E, Stolte M, Bayerdoerffer E (1997) Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 113(4):1087–1090 S0016508597004599 [pii]PubMedGoogle Scholar
  127. Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Vera P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C (2012) Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30(2):184–190. doi: 10.1200/JCO.2011.38.2648 JCO.2011.38.2648 [pii]PubMedGoogle Scholar
  128. Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferme C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51. doi: 10.1016/S0140-6736(10)62175-7 S0140-6736(10)62175-7 [pii]PubMedGoogle Scholar
  129. Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, Farber LR, Kiehl RK, Cardinale J, Cooper DL (1996) Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14(9):2435–2443PubMedGoogle Scholar
  130. Sasse S, Klimm B, Gorgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Muller RP, Diehl V, Eich HT, Borchmann P, Engert A (2012) Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin’s lymphoma. Ann Oncol. doi: 10.1093/annonc/mds110 mds110 [pii]PubMedGoogle Scholar
  131. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496–5504. doi: 10.1182/blood-2008-01-134270 blood-2008-01-134270 [pii]PubMedGoogle Scholar
  132. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114(17):3533–3537. doi: 10.1182/blood-2009-05-220095 blood-2009-05-220095 [pii]PubMedGoogle Scholar
  133. Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM (2011) Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118(17):4585–4590. doi: 10.1182/blood-2011-07-365932 blood-2011-07-365932 [pii]PubMedGoogle Scholar
  134. Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bolling T, Dieckmann K, Potter R, Heinecke A, Bramswig J, Dorffel W (2010) Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55(6):1145–1152. doi: 10.1002/pbc.22664 PubMedGoogle Scholar
  135. Schlembach PJ, Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD (2000) Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 48(4):1107–1110 S0360-3016(00)00760-4 [pii]PubMedGoogle Scholar
  136. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJ, Willemze R (2007a) Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25(12):1581–1587. doi: 10.1200/JCO.2006.09.6396 JCO.2006.09.6396 [pii]PubMedGoogle Scholar
  137. Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R (2007b) Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 143(12):1520–1526. doi: 10.1001/archderm.143.12.1520 143/12/1520 [pii]PubMedGoogle Scholar
  138. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5):1600–1609. doi: 10.1182/blood-2008-04-152850 blood-2008-04-152850 [pii]PubMedGoogle Scholar
  139. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25(30):4730–4735. doi: 10.1200/JCO.2007.12.5062 25/30/4730 [pii]PubMedGoogle Scholar
  140. Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N (2005) Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62(3):809–813. doi: 10.1016/j.ijrobp.2004.12.043 S0360-3016(04)03166-9 [pii]PubMedGoogle Scholar
  141. Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH (2011) Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 22(5):1164–1169 10.1093/annonc/mdq574mdq574 [pii]PubMedGoogle Scholar
  142. Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte Trials. J Clin Oncol 30(32):3939–3946. doi: 10.1200/JCO.2012.42.2345 JCO.2012.42.2345 [pii]PubMedGoogle Scholar
  143. Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, Wilson LD (2004) Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 22(4):634–639. doi: 10.1200/JCO.2004.08.044 JCO.2004.08.044 [pii]PubMedGoogle Scholar
  144. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265PubMedGoogle Scholar
  145. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19(2):414–419PubMedGoogle Scholar
  146. Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104(12):3483–3489PubMedGoogle Scholar
  147. Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96(9):2993–3000PubMedGoogle Scholar
  148. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18(3):498–509PubMedGoogle Scholar
  149. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, Rohatiner AZ, Linch DC (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206–214. doi: 10.1093/jnci/djk029 99/3/206 [pii]PubMedGoogle Scholar
  150. Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W (2009) Duvic M (2012) Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to. Clin Cancer Res 18(18):5051–5060. doi: 10.1158/1078-0432.CCR-12-0604 1078-0432.CCR-12-0604 [pii]Google Scholar
  151. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994Google Scholar
  152. Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr (1991) Second cancers following non-Hodgkin’s lymphoma. Cancer 67(7):2002–2009PubMedGoogle Scholar
  153. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29(23):3194–3200. doi: 10.1200/JCO.2011.35.0736 JCO.2011.35.0736 [pii]PubMedGoogle Scholar
  154. Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21(22):4157–4164PubMedGoogle Scholar
  155. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107(1):108–115. doi: 10.1002/cncr.21971 PubMedGoogle Scholar
  156. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853–2858. doi: 10.1200/JCO.2009.26.5827 JCO.2009.26.5827 [pii]PubMedCentralPubMedGoogle Scholar
  157. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC (1994) Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69(6):1088–1093PubMedCentralPubMedGoogle Scholar
  158. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 30(9):907–913. doi: 10.1200/JCO.2011.38.5807 JCO.2011.38.5807 [pii]Google Scholar
  159. Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundstrom C, Christensson B, Sander B (2012) Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 156(2):225–233. doi: 10.1111/j.1365-2141.2011.08942.x PubMedGoogle Scholar
  160. Wahner-Roedler DL, Nelson DF, Croghan IT, Achenbach SJ, Crowson CS, Hartmann LC, O’Fallon WM (2003) Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo clinic experience. Mayo Clin Proc 78(6):708–715. doi: 10.4065/78.6.708 S0025-6196(11)62460-9 [pii]PubMedGoogle Scholar
  161. Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98(10):2930–2934PubMedGoogle Scholar
  162. Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT (2000) Management of breast cancer after Hodgkin’s disease. J Clin Oncol 18(4):765–772PubMedGoogle Scholar
  163. Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH (2009) Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol 145(6):667–674 10.1001/archdermatol.2009.74145/6/667 [pii]PubMedGoogle Scholar
  164. Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdorffer E, Stolte M, Neubauer A (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23(31):8018–8024. doi: 10.1200/JCO.2005.02.3903 JCO.2005.02.3903 [pii]PubMedGoogle Scholar
  165. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, Osborne MP, Kinne DA, Rosen PP (1992) Breast cancer in patients irradiated for Hodgkin’s disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 10(11):1674–1681PubMedGoogle Scholar
  166. Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, Ahn JS, Kim YK, Bom HS, Chung IJ, Kim HJ, Lee JJ (2011) Prognostic significance of interim (1)(8)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 47(9):1312–1318. doi: 10.1016/j.ejca.2010.12.027 S0959-8049(11)00038-4 [pii]PubMedGoogle Scholar
  167. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 28(14):2373–2380. doi: 10.1200/JCO.2009.26.2493 PubMedGoogle Scholar
  168. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG (2006) Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 24(9):1376–1382. doi: 10.1200/JCO.2005.03.6285 JCO.2005.03.6285 [pii]PubMedGoogle Scholar
  169. Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, Derenzini E, Quirini F, Baccarani M (2011) Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 117(5):1010–1018. doi: 10.1002/cncr.25579 PubMedGoogle Scholar
  170. Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S (2012) Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39(1):4–12. doi: 10.1007/s00259-011-1916-8 PubMedGoogle Scholar
  171. Zittoun R, Audebert A, Hoerni B, Bernadou A, Krulik M, Rojouan J, Eghbali H, Merle-Beral H, Parlier Y, Diebold J et al (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3(2):207–214PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Duke Cancer InstituteDuke University Medical CenterDurhamUSA
  2. 2.Department of Therapeutic RadiologyYale University School of MedicineNew HavenUSA

Personalised recommendations